LINCOLN, Neb., Aug. 8, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that it has released an extensive selection of new genetic tests through Paw Print Genetics® and Canine HealthCheck® solutions.
"These new tests can identify genetic sequences associated with potential diseases and other traits and can provide invaluable insights into a canine's genetic composition," said Dr. Robert Westra, Associate Medical Director at Neogen. "With the introduction of these tests, Neogen has elevated the landscape of comprehensive canine genetic screening, enabling veterinarians, breeders, and pet owners to learn more about their animals, facilitating informed decisions regarding their health and wellbeing."
Dedicated to the continuous advancement of canine health and wellbeing, Paw Print Genetics has introduced 49 new tests, increasing its full testing portfolio to nearly 350 breed-specific tests.
These new tests include:
Canine HealthCheck has introduced 69 new tests, increasing its full testing portfolio to over 325 diseases and traits.
These new tests include:
Neogen's canine genetic tests allow for profound insights into color and trait genotypes as well as identifying genetic mutations associated with disease. Results are reported as normal, carrier, or at-risk/affected, which can provide extensive information about a dog's genetic makeup.
Paw Print Genetics and Canine HealthCheck tests are available for purchase starting today on the Paw Print Genetics and Canine Health Check websites. For more information, please visit Neogen's website, contact the customer support team at This email address is being protected from spambots. You need JavaScript enabled to view it., or call 509-483-5950.
About Neogen
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The Company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.
Media Contact
Maree Smith, Marketing Manager, Genomics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.39 |
Daily Change: | -0.21 -4.57 |
Daily Volume: | 12,316,827 |
Market Cap: | US$952.370M |
January 21, 2025 January 10, 2025 December 17, 2024 October 10, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load